Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Mymetics Corporation

Market Cap 439K 379K 348K 328K 616K 41.41M 621K 4.12M 1.61M 20.32M 1.65M 1.61M 70.3M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.22M 57.2M 53.84M 101M 6.81B 102M 678M 264M 3.34B 271M 265M 11.56B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0.0003
0
1 year 0
Extreme 0.0003
0
3 years 0
Extreme 0.0003
56.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-100.00% 45
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+2.73%+6.31%-12.75%-16.70% 22.63B
+5.95%+6.44%-2.48%+383.89% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
-2.54%-0.57%+26.42%+176.03% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-7.73%+6.58%+79.67%+104.65% 11.56B
Average +0.81%+0.63%+23.27%+69.18% 20.97B
Weighted average by Cap. +1.39%+0.51%+32.03%+90.05%

Financials

2021 2022
Net sales 430K 371K 341K 321K 603K 40.58M 608K 4.04M 1.57M 19.92M 1.61M 1.58M 68.9M 1.03M 887K 815K 767K 1.44M 97.02M 1.45M 9.66M 3.76M 47.61M 3.86M 3.78M 165M
Net income -4.73M -4.08M -3.75M -3.53M -6.64M -446M -6.69M -44.46M -17.31M -219M -17.75M -17.37M -758M -4.8M -4.15M -3.81M -3.59M -6.74M -453M -6.8M -45.16M -17.58M -223M -18.03M -17.65M -770M
Net Debt 67.1M 57.89M 53.22M 50.09M 94.13M 6.33B 94.92M 631M 246M 3.11B 252M 246M 10.75B 71.68M 61.84M 56.86M 53.51M 101M 6.77B 101M 674M 262M 3.32B 269M 263M 11.49B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!